+ Site Statistics
+ Search Articles
+ PDF Full Text Service
How our service works
Request PDF Full Text
+ Follow Us
Follow on Facebook
Follow on Twitter
Follow on LinkedIn
+ Subscribe to Site Feeds
Most Shared
PDF Full Text
+ Translate
+ Recently Requested

Accuracy of FDG-PET/CT and paraneoplastic antibodies in diagnosing cancer in paraneoplastic neurological syndromes

Accuracy of FDG-PET/CT and paraneoplastic antibodies in diagnosing cancer in paraneoplastic neurological syndromes

Revista Espanola de Medicina Nuclear E Imagen Molecular 35(1): 17-21

There is still no consensus about whether to perform PET/CT to detect carcinoma in paraneoplastic neurological syndromes (PNS) in patients with or without antibodies. The aim of this study is to determine the diagnostic accuracy of PET/CT and antibodies in patients with PNS. A retrospective study was conducted on patients with clinically suspected PNS between 2008 and 2013. The association between histopathological findings, paraneoplastic antibodies, and PET/CT findings were evaluated. Sensitivity and specificity for the detection of underlying malignancy were calculated for PET/CT and paraneoplastic antibodies. A total of 42 patients were analyzed. Of these 42 patients, 32 (75%) had a classical PNS, 6 (14%) had positive PET/CT findings, and 34 were tested for the presence of antibodies (anti-Hu Ab, anti-Yo Ab, and anti-Ri Ab). Twenty one of 34 patients had positive antibodies. Of the 6 patients with positive PET/CT findings, 6 had positive histopathological results. Among 21 patients with positive biomarkers, carcinoma was confirmed only in 5 patients. One patient with negative antibodies, but positive PET/CT findings, was diagnosed with a tumor. Gastric carcinoma was detected in 1 patient with negative PET/CT findings and antibodies during follow-up. Based on the results, PET/CT was found to have 85.71% sensitivity, 100% specificity, 100% positive and 97.22% negative predictive values in the detection of tumors. PET/CT has a certain diagnostic accuracy for detecting underlying malignancy in patients with PNS, regardless of the presence of paraneoplastic antibodies.

Please choose payment method:

(PDF emailed within 0-6 h: $19.90)

Accession: 057121181

Download citation: RISBibTeXText

PMID: 26260889

DOI: 10.1016/j.remn.2015.07.001

Related references

Autoimmune paraneoplastic syndromes associated to lung cancer: A systematic review of the literature: Part 3: Neurological paraneoplastic syndromes, involving the central nervous system. Lung Cancer 106: 83-92, 2017

Recombinant immunoblot for assessment of intrathecally synthesised paraneoplastic antineuronal antibodies in cerebrospinal fluid from patients with paraneoplastic neurological syndromes. Clinical Chemistry and Laboratory Medicine 46(12): 1793-1795, 2008

Autoimmune paraneoplastic syndromes associated to lung cancer: A systematic review of the literature Part 4: Neurological paraneoplastic syndromes, involving the peripheral nervous system and the neuromuscular junction and muscles. Lung Cancer 111: 150-163, 2017

A nationwide survey on paraneoplastic neurological syndromes. Project group on paraneoplastic neurological syndromes, Neuroimmunological Disease Research Committee, the Ministry of Health and Welfare, Japan. Rinsho Shinkeigaku 37(2): 93-98, 1997

Paraneoplastic neurological syndromes and breast cancer. Regression of paraneoplastic neurological sensorimotor neuropathy in a patient with metastatic breast cancer treated with capecitabine: a case study and mini-review of the literature. Breast Cancer Research and Treatment 105(2): 133-138, 2007

Diagnostic accuracy of different immunological methods for the detection of antineuronal antibodies in paraneoplastic neurological syndromes. Immunological Investigations 39(2): 186-195, 2010

Prostate cancer, Hu antibodies and paraneoplastic neurological syndromes. Journal of Neurology 263(5): 1001-1007, 2016

Paraneoplastic neurological syndromes in lung cancer patients with or without onconeural antibodies. Journal of the Neurological Sciences 348(1-2): 41-45, 2015

Paraneoplastic neurological syndromes. "Transverse myelitis or paraneoplastic myelomalacia". Il Fracastoro 61(1): 47-54, 1968

Onco-neural antibodies and tumour type determine survival and neurological symptoms in paraneoplastic neurological syndromes with Hu or CV2/CRMP5 antibodies. Journal of Neurology Neurosurgery and Psychiatry 80(4): 412-416, 2009

Three patients with a paraneoplastic neurological syndrome: the significance of paraneoplastic antibodies. Nederlands Tijdschrift Voor Geneeskunde 151(15): 874-880, 2007

Antineuron antibodies and paraneoplastic neurological syndromes. Revue Neurologique 159(4): 463-465, 2003

Antibodies to TRIM46 are associated with paraneoplastic neurological syndromes. Annals of Clinical and Translational Neurology 4(9): 680-686, 2017

Anti-neuronal antibodies in neurological paraneoplastic syndromes. Journal of Neuroimmunology 16(1): 12-13, 1987

Antiamphiphysin antibodies are associated with various paraneoplastic neurological syndromes and tumors. Archives of Neurology 56(2): 172-177, 1999